Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trialsAlexa B. Kimball, Elisa Muscianisi, C. Paul et al.|The Lancet|2023Cited by 318
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week resultsNina Magnolo, Manmath Patekar, Külli Kingo et al.|Journal of the American Academy of Dermatology|2021Cited by 50
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized StudyNina Magnolo, Manmath Patekar, Külli Kingo et al.|Pediatric Drugs|2022Cited by 19